Common brand names

• Blenrep

How it is administered

Belantamab mafodotin is administered intravenously. The recommended dose is 2.5 mg/kg given once every 3 weeks as a 30-minute infusion. Patients should be premedicated with antihistamines and antipyretics to reduce the risk of infusion-related reactions. Ophthalmic examinations are required before each dose due to the risk of ocular toxicity.

How it works

Belantamab mafodotin is an antibody-drug conjugate (ADC) targeting B-cell maturation antigen (BCMA), which is highly expressed on multiple myeloma cells. The ADC consists of a humanized anti-BCMA monoclonal antibody linked to the cytotoxic agent monomethyl auristatin F (MMAF). Upon binding to BCMA-expressing cells, the ADC is internalized, releasing MMAF intracellularly. MMAF disrupts microtubule networks, leading to cell cycle arrest and apoptosis of malignant plasma cells.

Who should take it

Belantamab mafodotin is indicated for adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent. Patients meeting these criteria may benefit from belantamab mafodotin therapy as prescribed by their oncologist.

Who should not take it

Patients with a known hypersensitivity to belantamab mafodotin or any of its components should not receive this medication. Individuals with active ocular conditions or significant baseline visual impairment should consult their healthcare provider, as belantamab mafodotin is associated with ocular toxicity. Pregnant or breastfeeding women should avoid belantamab mafodotin due to potential harm to the fetus or neonate.

Commonly used with

Belantamab mafodotin is often used as monotherapy in the specified indication. However, it may be part of a broader treatment regimen that includes supportive care measures such as platelet transfusions for thrombocytopenia and artificial tears for ocular symptoms.

Commonly tested with

Clinical trials are evaluating belantamab mafodotin in combination with other agents, including:

• Immunomodulatory agents (e.g., lenalidomide)

• Proteasome inhibitors (e.g., bortezomib)

• Dexamethasone

These studies aim to assess potential synergistic effects and expand therapeutic options for patients.